BDR Pharma launches generic antibiotic /anti-bacterial range medicine Ceftazidime Avibactum
XAVITAZ is a combination of 2g Ceftazidime & 500mg Avibactam
BDR Pharmaceuticals has launched a new generic in the antibiotic range: Ceftazidime + Avibactum (brand name: XAVITAZ). It will be effective in treating gram-negative infections (hospital-acquired & ventilator-associated pneumonia, intra-abdominal infections, and Complicated UTIs)
XAVITAZ is a combination of 2g Ceftazidime & 500mg Avibactam, this combination is useful in treating resistant gram-negative infections, including those caused by Pseudomonas aeruginosa and many Ceftazidime-resistant strains.
Raheel Shah, Director of Business Development, BDR Group, stated, “Ensuring that all patients have access to quality-produced, world-class treatment was the main reason for launching the drug in India. BDR Pharma has a vision of strengthening the R&D department and works under the needs of the people. We are pleased with the launch of Ceftazidime Avibactum because it will add to the repertoire of physicians treating infections.”
